Biotech Values

[willyw]

AbbVie Presents New Phase 2 Data for Investigational, Once-Daily, Ribavirin-Free, Pan-Genotypic Regimen of ABT-493 and ABT-530 for Hepatitis C Genotypes 1-6

https://news.abbvie.com/news/abbvie-presents-new-phase-2-data-for-investigational-once-daily-ribavirin-free-pan-genotypic-regimen-abt-493-and-abt-530-for-hepatitis-c-genotypes-1-6.htm

"Apr 16, 2016
- 97-98 percent SVR12 achieved with eight weeks of ABT-493 and ABT-530 in genotypes 1-3 hepatitis C virus patients without cirrhosis in SURVEYOR-1 and 2 studies(1,2)
- 100 percent SVR12 achieved with 12 weeks of treatment in difficult-to-treat genotype 3 patients with compensated cirrhosis (Child-Pugh A) new to therapy (3)
- 100 percent SVR12 achieved with 12 weeks of treatment in genotypes 4-6 patients without cirrhosis; eight-week duration investigated in this ongoing study (4)"

===============
(my comment)
If you follow the link, you will see a table; these are all "optimized" dosing with 300mg ABT-493. The number of patients in each cohort is rather small, but given the high percentage rates the results are still going to cause a stir, IMHO. These is beginning to be enough other studies and cohorts to gain some confidence about the relative tolerability of the program, lack of serious AEs.

Compare the efficacy to Sov-Vel which should be approved by June; this looks better in efficacy.

If you extrapolate this to the trial straight up comparing to Sovaldi-Daclatasvir, this is also going to win in efficacy.

Comparing it to the new Gilead triple therapy it is less clear; it will need to be 8 weeks. It isn't clear how important 6 weeks is, nor what the results would be with a 3rd agent, or if that is important. Results in greater depth could come mid summer and for sure by AASLD in the fall.

There should be more on this; IMHO it is a big news story, perhaps particularly in G-3, which has been lagging in a superior therapy.
I very much agreed with Adam F about EASL being the Gilead show, due to the high number of studies w/ Sovaldi based therapies, but this may be one of the bigger breaking stories of EASL/Liver Congress